You have read all your free articles, to continue reading subscribe to read the rest of this content.
Alexion, AstraZeneca’s Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006. NI006 is an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)Already a subscriber Login You have read all your free articles, to…
Along with KTH Royal Institute of Technology and Lund University Doctrin and Capio are developing AI decision support tools helping healthcare professionals to prioritize, diagnose and treat patients. Doctrin develops digital tools to support healthcare providers, and the company has already deveAlready a subscriber Login You have read all your…
Asarina Pharma, a drug development company focused on the development of a novel therapy for severe premenstrual symptoms, has completed a financing round raising EURO 7 million from new and existing investors for the continued clinical development of Sepranolone. Around 5% of women in fertile agAlready a subscriber Login You…
The US FDA has cleared the novel interleukin-17 (IL-17) blocker izokibep (ABY-035) to proceed to Phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis. “Uveitis is one of the leading causes of blindness worldwide. Through the years, we have learned much about tAlready a subscriber Login You have read…
